Protozoan Parasitism : From Omics to Prevention and Control.

Intro -- Contents -- Preface -- 1. From Proteins to Molecular Targets: Trypanosoma cruzi Proteomic Insights in Drug Development -- Background -- T. cruzi and proteomics: more than a decade of studies -- Trypanocidal compounds: mechanism of action and resistance -- Molecular drug targets and promising antigens for vaccine development -- Past, present and future of Chagas disease chemotherapy -- 2. High-throughput Screenings: New Breeze in Anti-Trypanosoma cruzi Drug Discovery -- Introduction -- High-throughput screening -- Anti-T. cruzi HTS campaigns -- Next drug discovery steps -- Summary -- 3. Protein Glycosylation in Trypanosoma cruzi and Mass Spectrometry-Based Strategies for Glycan and Glycoprotein Characterization -- Introduction -- Landmarks of protein glycosylation in T. cruzi -- Mass spectrometry as a tool to study protein glycosylation in T. cruzi -- Glycomic and glycoproteomic studies on T. cruzi -- Conclusion -- 4. High-throughput Genetic Engineering in Trypanosoma cruzi -- Introduction -- The model system: setting the conditions for genetic engineering in kinetoplastid parasites -- High-throughput genetic engineering in kinetoplastid parasites -- Conclusion -- 5. Omics Approaches for Understanding Gene Expression in Leishmania: Clues for Tackling Leishmaniasis -- Introduction -- The Leishmania genome -- Regulation of gene expression in Leishmania -- Genomics and transcriptomics approaches -- Leishmania proteomics -- Metabolomics applied to the study of Leishmania -- Future trends -- 6. Natural Products in Human Leishmaniasis Therapy: Recent Advances -- Introduction -- Current chemotherapy for leishmaniasis -- Natural products as promising antileishmanial agents (last two years of research) -- Phenoles and steroles -- 7. Naegleria fowleri: Biology and Pathogenesis -- Cell biology and speciation.

Cellular differentiation in N. fowleri -- Growth and life cycle -- Ecology -- Primary amoebic meningoencephalitis -- Clinical and laboratory diagnosis -- Chemotherapeutic and disinfection strategies -- Pathogenesis -- The host-damage response to N. fowleri -- Conclusion and future studies -- 8. Entamoeba histolytica: from High-throughput Technology to New Drugs -- Introduction -- Assay development for drug discovery -- Compound screening in 96-well plates using an FDA-approved compound library -- Auranofin: an alternative to 'one bug-one drug' approach -- Auranofin: indications for approval in 1985 -- Recent clinical studies of auranofin -- Compound screening in 384-well plates using kinase-targeted compound collections -- Perspectives and challenges -- 9. Gene Silencing and Therapeutic Targets Against Acanthamoeba Infections -- Introduction -- Current status of therapy against Acanthamoeba -- Drug and therapeutic targets discovery in Acanthamoeba -- Drug sensitivity and activity screening -- Natural products against Acanthamoeba keratitis -- Gene silencing (RNAi) and novel drug target validation -- Future perspectives -- Current Books of Interest -- Index.

In this timely book expert international authors review the current hot-topics in this area to provide an up-to-date overview. The book is divided into two parts. The first part is dedicated to Trypanosoma cruzi, an organism not only responsible for a serious tropical disease but also a good model system for fundamental and applied biology research. Part two of the book is dedicated to four other important protozoa: Leishmania, Naegleria, Entamoeba and Acanthamoeba. Chapters are written from a molecular biology and genomics perspective and focus on a common goal: the development of new strategies for the control and prevention of infection. This volume is essential reading for anyone working on protozoan parasites in academia, government, and biotechnology companies.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.